WILLIAM (BILL) THOMAS TINO

Denver, Colorado (706) 372-1529 (cell) (720) 627-5369 (home) billt2266@msn.com

Scientist, Immunologist: Experience in Biomedical Research, Drug Discovery and Biotechnology TECHNICAL EXPERIENCE and SKILL SETS: detailed cellular immunology; in vitro cell-based assays; in vivo animal models; monoclonal antibody development-therapeutics, diagnostics; preclinical drug discovery-small molecule pharmaceutics, therapeutic antibodies, proteins; autoimmunity, inflammation, oncology, infectious diseases, vaccines; immunoassays/ELISA development; supervisory and project management experience. EDUCATION: Master of Science Immunology-Microbiology University of Montana, Missoula, MT Bachelor of Arts Major: Microbiology; Minor: Chemistry Rutgers University, New Brunswick, NJ EMPLOYMENT HISTORY: Cytoskeleton, Inc., Denver, CO April 2013-October 2013 Scientist I, Antibody Laboratory (temporary 6-month consulting position) Established a fully functional hybridoma/monoclonal antibody laboratory (rodent facility, cell culture lab, ELISA screening, antigen design) Initiated 3 monoclonal antibody projects: designed antigens, developed and implemented immunization strategies, serum screening and hybridoma fusions-generated monoclonal antibodies to post-translational protein modifications Abeome Corporation, Athens, GA April 2012-April 2013 Senior Scientist, Antibody Technology-Discovery and Development Successfully designed and implemented 3 custom antibody projects Designed and developed immunoassays (ELISAs) in support of custom antibody projects and basic research Characterized B-cell and plasma cell differentiation by flow cytometry in 3 transgenic mouse strains Researched and developed new technologies for the accelerated generation and discovery of monoclonal antibodies Ligocyte Pharmaceuticals, Bozeman, MT Senior Scientist, PreClinical Immunology June 2004-June 2011

Preclinical research and development (in vitro cell-based assays, in vivo models, immunoassays) of new vaccine formulations. Successfully characterized the T-cell and B-cell responses to vaccine antigen formulations (detailed in vitro cellular immunology; CD4/CD8 T-cell responses; ELISPOT assays, cytokine assays): respiratory syncytial virus (RSV), norovirus,

influenza, and anthrax. Result: understanding T-cell and B-cell responses to these vaccine antigens led to the development of more potent vaccine formulations. Successfully designed, developed and characterized memory B-cell assays for the Norovirus vaccine program. Result: this assay became a critical tool for monitoring patients immune response to the Norovirus vaccine in human vaccine clinical trials. Designed and developed immunoassays (ELISA, ELISPOT) for all vaccine programs. Developed an immunoaffinity method for purifying RSV F-antigen: a critical reagent for monitoring immune responses elicited by the RSV vaccine. Managed a multi-disciplinary group as project leader: successfully cloned and expressed several rabbit cytokine genes, generated and characterized monoclonal antibodies specific for the rabbit cytokines, developed immunodiagnostic reagents for their detection. Supervised, mentored and trained two full-time Research Associates. Icos Corporation, Bothell, WA July 1999 June 2003 Staff Scientist, PreClinical Studies Preclinical research and development (in vivo immunology models, in vitro cell-based assays) of small molecule pharmaceutics (signal transduction inhibitors) and therapeutic antibodies (anti-adhesion molecules). Designed, developed, and used in vitro cell-based immunological assays (T-cells; Bcells) for screening and testing small molecule signal transduction inhibitors specific for the delta isoform of PI3-kinase, a critical signaling enzyme for B-lymphocyte and neutrophil activation: screened over 800 compounds; identified lead compounds for advancement into preclinical testing. Determined mechanism of action (MOA): effect of PI3-kinase inhibitors on B-cell functions: antibody production, antigen-presenting function. Designed, developed, and used in vivo animal models of immune function (T-cells, Bcells, mast cells, neutrophils), autoimmune disease (rheumatoid arthritis, lupus, COPD) and inflammation. Result: validated and confirmed the in vivo cell-specific activity of the PI-3 kinase inhibitors-these results were critical for go/no go decision on therapeutic/disease indication. Supervised and trained two research associates. Northwest Biotherapeutics, Seattle, WA July 1995 July 1999 Manager and Project Leader, Hybridoma/Monoclonal Antibody Laboratory Generation, characterization, and development of monoclonal antibodies for the immunotherapy and diagnosis of prostate cancer. Generated, characterized, and developed over 10 new fully human monoclonal antibodies for the immunotherapy and immunoimaging of prostate cancer. Generated, characterized, and developed over 40 new mouse monoclonal antibodies and mouse monoclonal antibodies for the immunodiagnosis of prostate cancer. Determined antibody effector functions: internalization into target tumor cells, apoptosis induction in tumor cells, ADCC, and binding to viable tumor cells.

Tested therapeutic antibody candidates in a preclinical mouse tumor model (nude mouse xenograft model). Supervised and trained two research associates and two research technicians. PROFESSIONAL DEVELOPMENT COURSES: Pharmacokinetic Concepts in Drug Development. Pharmaceutical Education and Research Institute. April 2001. Philadelphia, PA. ICOS Management Development Program: Developing Self, Others, and Groups More Effectively. November 2000. Icos Corporation, Bothell, WA. Matt Mirasola, Instructor. The Dale Carnegie Class. October 1998-January 1999. Crace and Associates, Bellevue, WA. Flow Cytometry: FACSCalibur Training, Becton-Dickinson Immunocytometry Systems, San Jose, CA, 1997.

PATENTS: Richardson, C, Vedvick, T, Tino, WT, Foubert T. Norovirus Vaccine Formulations. Filed on September 28, 2007. Pending as PCT/US2007/79929. Yashwant, D, Graziano, R, Hudson, D, Holmes, EH, Tino, WT. Human Monoclonal Antibodies to Prostate Specific Membrane Antigen. Filed on July 26, 2000. Murphy, GP, Boynton, AL, Holmes, EH, Tino, WT. Monoclonal Antibodies Specific for the Extracellular Domain of Prostate Specific Membrane Antigen. Filed on March 25, 1997. Rice, GC, Bursten, SL, Singer, JW, Tino, WT. Method for Selectively Inhibiting IL-2 Signal Transduction. Filed on November 12, 1993.

PUBLICATIONS: Additional publications available upon request Puri, KD, Doggett, TA, Douangpanya, J, Hou, Y, Tino, WT, Wilson, T, Graf, T, Clayton, E, Turner, M, Hayflick, JS, Diacovo, TG. Mechanisms and implications of phosphoinositide 3kinase in promoting neutrophil trafficking into inflamed tissue. Blood May 1; 103 (9): 3448-56. 2004. Sadhu, C, Dick, K, Tino, WT and Staunton, DE. Selective role of PI3Kdelta in neutrophil inflammatory responses. Biochemical and Biophysical Research Communications 308: 764769, 2003. Tino, WT, et al. Isolation and Characterization of Monoclonal Antibodies for Protein Conformational Epitopes Present in Prostate-Specific Membrane Antigen. Hybridoma 19: 249257, 2000.